Traws Pharma (TRAW) Price & Analysis

Compare

1,856 Followers

TRAW Stock Chart & Stats

$1.96

-$0.87(-9.63%)

At close: Jan 08 4:00 PM EST

$1.96

-$0.87(-9.63%)

Day’s Range― - ―

52-Week Range$0.97 - $8.61

Previous CloseN/A

Volume35.69K

Average Volume (3M)206.36K

Market Cap

$15.66M

Enterprise Value-$4.17M

Total Cash (Recent Filing)$13.08M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)<0.1

Beta0.53

Next Earnings

Mar 12, 2026

EPS Estimate

-1.22

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.34

Shares Outstanding7,990,867

10 Day Avg. Volume403,079

30 Day Avg. Volume206,356

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)-0.44

Price to Sales (P/S)61.01

P/FCF Ratio-0.46

Enterprise Value/Market Cap-0.27

Enterprise Value/Revenue-1.49

Enterprise Value/Gross Profit-1.49

Enterprise Value/Ebitda0.38

Forecast

1Y Price Target

$7.25

Price Target Upside269.90% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trial ResultsPhase two interim analysis showed ratutrelvir achieved symptom resolution comparable to Paxlovid, was generally better tolerated, and had no observed symptom or virologic rebound, supporting a strong clinical profile.

Market Access And Patient EligibilityRatutrelvir's design to avoid common drug interactions that prevent a sizable portion of older and comorbid patients from receiving Paxlovid could expand the addressable patient population and uptake.

Pharmacology And Resistance ProfilePhase one and laboratory data indicated favorable safety without metabolic induction, demonstrated higher antiviral potency than the leading comparator, and retained activity against resistance-associated mutations, suggesting potential durability against emerging variants.

Bears Say

Traws Pharma News

Traws Pharma initiated with a Buy at Ladenburg

Ladenburg initiated coverage of Traws Pharma (TRAW) with a Buy rating and $6.50 price target The firm says...

11d ago

TRAW

Traws Pharma completes enrollment in Phase 2 study of ratutrelvir

Traws Pharma (TRAW) announced the completion of enrollment in its ongoing 90-patient, open-label Phase 2 study of ratutrelvir,...

15d ago

TRAW

Traws Pharma files tivoxavir marboxil IND application with U.S. FDA

Traws Pharma (TRAW) announced the filing of a U.S. IND application with the U.S. Food and Drug Administration,...

28d ago

TRAW

Traws Pharma Completes Phase 2 Enrollment for COVID Candidate

An announcement from Traws Pharma ( ($TRAW) ) is now available. On January 26, 2026, Traws Pharma reported...

15d ago

TRAW

Traws Pharma’s TRX-100 Phase 1 Completion: A Quiet but Key Milestone for Investors

Traws Pharma, Inc. ($TRAW) announced an update on their ongoing clinical study. Traws Pharma’s TRX-100 Phase 1 Readout:...

20d ago

TRAW

Traws Pharma advances flu and COVID-19 antiviral pipeline

Traws Pharma ( ($TRAW) ) has provided an announcement. On January 13, 2026, Traws Pharma filed a U.S....

28d ago

TRAW

Promising Phase 2 Results for Ratutrelvir Highlight Clinical and Market Differentiation in COVID-19 Treatment

In a report released today, Brandon Folkes from H.C. Wainwright reiterated a Buy rating on Traws Pharma, with...

2M ago

TRAW

Traws Pharma Reports Positive Phase 2 Trial Results

An announcement from Traws Pharma ( ($TRAW) ) is now available. Traws Pharma announced positive interim results from...

2M ago

TRAW

Traws Pharma reports ‘positive’ interim data with ratutrelvir vs. paxlovid

Traws Pharma (TRAW) announced that interim data with ratutrelvir, an investigational oral, ritonavir-free Mpro/3CL protease inhibitor, demonstrated a...

2M ago

TRAW

Traws Pharma Approves Executive Stock Options

The latest announcement is out from Traws Pharma ( ($TRAW) ). On December 12, 2025, Traws Pharma‘s Compensation...

2M ago

TRAW

Traws Pharma initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Brandon Folkes initiated coverage of Traws Pharma (TRAW) with a Buy rating and $8 price...

2M ago

TRAW

Traws Pharma Holds Virtual Annual Meeting 2025

Traws Pharma ( ($TRAW) ) has shared an announcement. On November 21, 2025, Traws Pharma held its Annual...

2M ago

TRAW

Traws Pharma Reports Q3 2025 Progress and Cost Reductions

Traws Pharma, Inc. ( ($TRAW) ) has released its Q3 earnings. Here is a breakdown of the information...

3M ago

TRAW

Traws Pharma Reports Q3 2025 Financial Results

The latest update is out from Traws Pharma ( ($TRAW) ). On November 13, 2025, Traws Pharma announced...

3M ago

TRAW

TRAW FAQ

What was Traws Pharma’s price range in the past 12 months?

Traws Pharma lowest stock price was $0.97 and its highest was $8.61 in the past 12 months.

What is Traws Pharma’s market cap?

Traws Pharma’s market cap is $15.66M.

When is Traws Pharma’s upcoming earnings report date?

Traws Pharma’s upcoming earnings report date is Mar 12, 2026 which is in 30 days.

How were Traws Pharma’s earnings last quarter?

Traws Pharma released its earnings results on Nov 13, 2025. The company reported -$0.34 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.34.

Is Traws Pharma overvalued?

According to Wall Street analysts Traws Pharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Traws Pharma pay dividends?

Traws Pharma does not currently pay dividends.

What is Traws Pharma’s EPS estimate?

Traws Pharma’s EPS estimate is -1.22.

How many shares outstanding does Traws Pharma have?

Traws Pharma has 7,990,867 shares outstanding.

What happened to Traws Pharma’s price movement after its last earnings report?

Traws Pharma reported an EPS of -$0.34 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -17.29%.

Which hedge fund is a major shareholder of Traws Pharma?

Currently, no hedge funds are holding shares in TRAW

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Traws Pharma

Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

Traws Pharma (TRAW) Earnings & Revenues

Historic Earnings Reports

TRAW Stock 12 Month Forecast

Average Price Target

$7.25

▲(269.90% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","21":"$21","5.25":"$5.25","10.5":"$10.5","15.75":"$15.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,5.25,10.5,15.75,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.04,2.4984615384615383,2.956923076923077,3.4153846153846157,3.873846153846154,4.332307692307692,4.7907692307692304,5.24923076923077,5.707692307692308,6.166153846153846,6.624615384615384,7.0830769230769235,7.541538461538462,{"y":8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.04,2.440769230769231,2.8415384615384616,3.2423076923076923,3.643076923076923,4.043846153846154,4.444615384615385,4.845384615384615,5.246153846153846,5.646923076923077,6.047692307692308,6.4484615384615385,6.849230769230769,{"y":7.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.04,2.3830769230769233,2.726153846153846,3.069230769230769,3.4123076923076923,3.7553846153846155,4.098461538461539,4.441538461538461,4.7846153846153845,5.127692307692308,5.47076923076923,5.813846153846153,6.156923076923077,{"y":6.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":16,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.48,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.75,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.26,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.58,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.99,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.2,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.88,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.28,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.14,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.48,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.13,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.04,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 44, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >